Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in …
Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $82,990 and sold $8.56M worth of Arrowhead Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $103,722 and sold $24.69M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lu Hongbo (director) — $165,980.
The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.
2024-07-02 | Sale | Chief Commercial Officer | 9,394 0.0073% | $25.28 | $237,480 | 0.00% | ||
2024-05-02 | Sale | director | 1,799 0.0014% | $23.31 | $41,935 | -2.20% | ||
2024-04-01 | Sale | Chief Discovery/Trans Medicine | 6,000 0.0048% | $28.03 | $168,180 | -15.79% | ||
2024-03-20 | director | 1,000 0.0008% | $27.50 | $27,500 | -15.06% | |||
2024-03-19 | director | 1,000 0.0008% | $28.00 | $28,000 | -13.77% | |||
2024-03-18 | director | 1,000 0.0008% | $27.49 | $27,490 | -14.94% | |||
2024-03-06 | Sale | Chief Financial Officer | 40,000 0.0323% | $35.19 | $1.41M | -32.28% | ||
2024-01-31 | Sale | Chief Executive Officer | 57,499 0.0525% | $32.35 | $1.86M | -22.99% | ||
2024-01-12 | Sale | Chief Discovery/Trans Medicine | 7,940 0.0075% | $36.89 | $292,904 | -31.55% | ||
2024-01-11 | Sale | director | 2,911 0.0028% | $38.06 | $110,788 | -33.50% | ||
2024-01-11 | Sale | director | 3,147 0.003% | $38.06 | $119,787 | -33.50% | ||
2024-01-11 | Sale | director | 3,934 0.0037% | $38.07 | $149,759 | -33.50% | ||
2024-01-11 | Sale | director | 4,720 0.0045% | $38.10 | $179,813 | -33.50% | ||
2024-01-05 | Sale | COO and General Counsel | 22,841 0.021% | $35.27 | $805,716 | -29.89% | ||
2024-01-05 | Sale | Chief Financial Officer | 16,104 0.0148% | $35.27 | $567,910 | -29.89% | ||
2024-01-05 | Sale | 32,143 0.0295% | $35.18 | $1.13M | -29.89% | |||
2024-01-05 | Sale | Chief Medical Officer | 8,303 0.0076% | $35.26 | $292,804 | -29.89% | ||
2024-01-05 | Sale | Chief Commercial Officer | 74 <0.0001% | $33.89 | $2,508 | -29.89% | ||
2024-01-04 | Sale | COO and General Counsel | 1,600 0.0014% | $32.63 | $52,208 | -26.93% | ||
2024-01-03 | Sale | COO and General Counsel | 8,749 0.0082% | $32.28 | $282,439 | -20.57% |
Anzalone Christopher Richard | Chief Executive Officer | 3715048 2.9884% | $18.37 | 4 | 35 | <0.0001% |
Myszkowski Kenneth Allen | Chief Financial Officer | 400600 0.3222% | $18.37 | 1 | 27 | <0.0001% |
GIVEN DOUGLAS B | director | 129711 0.1043% | $18.37 | 1 | 19 | <0.0001% |
Ferrari Mauro | director | 60778 0.0489% | $18.37 | 2 | 4 | +71% |
Lu Hongbo | director | 33680 0.0271% | $18.37 | 3 | 0 |
BlackRock | $438.91M | 12.36 | 15.35M | +15.36% | +$58.43M | 0.01 | |
The Vanguard Group | $354.76M | 9.99 | 12.4M | +16.23% | +$49.53M | 0.01 | |
Avoro Capital Advisors Llc | $244.69M | 6.89 | 8.56M | +657.13% | +$212.37M | 2.93 | |
State Street | $187.64M | 5.28 | 6.56M | -3.87% | -$7.56M | 0.01 | |
Fidelity Investments | $182.89M | 5.15 | 6.39M | +89.68% | +$86.47M | 0.01 |